....and have NO idea why it has been making me money over the last 6 weeks.
I'm not sure whether that means I'm dumb or smart!?
Can someone give a brief "pumpers" guide to the long thesis? Id on't know whether to grab the next $45 opportunity or hang firm for something.
The only reason you do a deal at $12 if you are a buyer underwriting that deal is that you believe (on the basis of data) that you are being offered an attractive discount and that you are being given free money and will make more.
Dangit - that sucks. I just bought 10k today - wish I'd held off until tomorrow.
Other than that though - no big deal.
Having decided to commercialize, they need money. What's your problem?
Could have had 3.85 for my 26,000 shares this week, but like a #$%$ - got from 3.72 down to 3.52
HOW could I be dumb enough after reading the presentation to see any possibility of an upside in the next 6-9 months?
Zero and out. GLTA.
Market reaction to what SEEMS to be a stinky Q4 (following a Q3) is odd to say the least.........
Nothing in their presentation is encouraging except future hopes and dreams around cancer.
I can only assume that either the market is ready to spread some of its FMI money around OR the dull JPM presentation - as well as being pretty discouraging for longs, doesn't really contain anything to give the shorts hope (and they're covering just because),
Btomm is getting really grumpy about the fact that some pretty dismal Q4 results are being met, mostly with green.
50+ messages yesterday and 15 so far today clearly indicates the level of obsession.
Sorry bud - the market has decided that this is a cancer detection stock now and it doesn't look like they are listening to your scaremongering........
OK - poor Q4 (following a poor Q3) but someone way smarter is betting on cancer detection.
You have to work awfully hard for your few red cents Ben.
They'll come in handy when the cancer tests start to explode.
In years to come, SQNM should be a genetic cancer testing company that does some NIP tests to deliver some cash.
the check out the FMI story today.
JPM investors are going to be looking for the next shoe to fall in cancer genetic testing and SQNM could have a nice week.
The market seems OK with it and you can guarantee that people with deep pockets read the presentation before you did.
I'd guess that the oncology stuff later in the presentation is what is keeping this neutral to positive today.
NIPT is becoming yesterday's news and no more than a cash cow that will fuel the next SQNM wave (hopefully!) in cancer testing.
From the NIPT point of view, this is really kind of a dead duck - lacklustre growth and unexciting profit (at least until medium risk gets some kind of ACOG push).
Cancer however - that is a whole new ball game that with a bit of speculation could double pps without any kind of change in financial metrics.
The 8k is certainly a worthwhile read.
It's a disaster for anyone with a short thesis that calls for SQNM to go bust (or even much lower than here), but I think it also limits SQNM's upside to single digits (albeit that could be a double from here).
Plenty of the short float is from higher than here - but anyone lower is going to need some Zantac to see them through the weekend.
I think right-to-lifer - and they only had to pay about $300 on the "dark web" to find some contractor to program it for them.
If there's anyone to be angry at - that would be Yahoo.
40% would be better - but you really have to know when to seize some profit.
About 70% of the uncertainty around the stock has now be eliminated. The market likes that - but the only people who like certainty more than the market are the people who have to make decisions on who/what/whether/when to acquire - and they can now remove the SQNM "hide slides" from their deck.
This will be acquired in the first half of 2015.
I guess we have to remember that some of yesterday's stock price reflected a hope that SQNM would prevail in the IP battle - and so you have to offset the loss of that "monopoly" potential against the gain of $50 million?
I think what maybe some are under appreciating is the fact that neither ILMN (which is a smart company by any reckoning) or SQNM did this deal for any reason other than to crush other competitors.
My spider senses tell me that with the acquisition of Ariosa by Roche - hardly a charity - $AUSP will be creeping up over the next few quarters.
Is no longer owned by SQNM (not that it ever seemed to be anyway).
"The parties will pool their owned and in-licensed intellectual property directed to noninvasive prenatal testing (NIPT), including patents that will remain the subject of ongoing interference proceedings."
However, maybe ILMN will add their muscle to enforcing the POOLED IP. More bad news for Roche.